EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort

Antonella d'Arminio Monforte iD, Alessandro Tavelli iD, Roberto Rossotti iD, Roberta Gagliardini, Annalisa Saracino, Sergio Lo Caputo, Matteo Sala, Eugenia Quiros-Roldan, Cristina Mussini, Enrico Girardi, Alessandro Cozzi-Lepri, Andrea Antinori und 2 weitere

Liver International · 2023

DOI: 10.1111/liv.15700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Antonella d'Arminio Monforte und 13 weiteren Autor:innen. Beteiligte Einrichtung: Icona Foundation, Milan, Italy. Hauptthemen laut MEDLINE: COVID-19, Hepatitis C, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Whether the HCV test‐and‐treat strategy impacted on the rate of new HCV infections among PLWH in Italy is unknown.

Methods

Prospective study of PLWH in the ICONA network. At baseline, PLWH were tested for HCV‐Ab; HCV‐RNA (if HCV‐Ab positive) and, if positive, treated with DAA. SVR12 indicated eradication. Seroconversions and re‐infections were evaluated yearly in HCV‐Ab neg and HCV‐RNA neg at first screening. We estimated the following: HCV seroconversions, incidence of HCV reinfections, and access to DAA and SVR12 rates tighter with factors associated with each outcome. Data were analysed by Cox regression, Poisson regression and logistic regression models.

Results

Sixteen thousand seven hundred and forty‐three PLWH were included; 27.3% HCV‐Ab positive; of these, 39.3% HCV‐RNA positive. HCV seroconversion incidence: .48/100 PYFU (95% CI: .36–.65); re‐infections incidence: 1.40/100 PYFU (95% CI: .91–2.04). The risk factor for HCV re‐infection was young age: aIRR 1.85, 95% CI: 1.17–2.95) per 10 years younger. 86.4% of HCV viremic in follow‐up started DAA. PWID vs. heterosexuals (aHR .75, 95% CI .62–.90), HIV‐RNA >50 copies/mL (aHR .70, 95% CI .56–.87), HCV genotype other than G1, G2, G3, G4 or with multiple/missing HCV genotype and post‐COVID‐19 calendar periods were associated with lower DAA access. 922/965 (95.5%) PLWH achieved SVR12. We estimated 72% reduction of chance to achieve SVR12 in PLWH with a CD4 count

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hepatitis CHIV InfectionsHumansChildAntiviral AgentsProspective StudiesReinfectionRNAViremia

Stichwörter der Autor:innen

HCVPLWHeradicationreinfectionsseroconversions

Substanzen

Antiviral AgentsRNA

Autor:innen und Institutionen

  • Icona Foundation, Milan, Italy.
  • Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari, University Hospital Policlinico, Bari, Italy.
  • Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Unit of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.

ORCID-Profile: Antonella d'Arminio Monforte, Alessandro Tavelli, Roberto Rossotti, Massimo Puoti

Förderung

  • Gilead Sciences

Zitieren

APA

d'Arminio Monforte, A., Tavelli, A., Rossotti, R., Gagliardini, R., Saracino, A., Lo Caputo, S., Sala, M., Quiros-Roldan, E., Mussini, C., Girardi, E., Cozzi-Lepri, A., Antinori, A., Puoti, M., & NoCo Study of the Icona cohort (2023). Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort. Liver International. https://doi.org/10.1111/liv.15700

Vancouver

d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, et al. Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort. Liver International. 2023. doi:10.1111/liv.15700

BibTeX
@article{dArminioMonforte2023,
  author = {d'Arminio Monforte, Antonella and Tavelli, Alessandro and Rossotti, Roberto and Gagliardini, Roberta and Saracino, Annalisa and Lo Caputo, Sergio and Sala, Matteo and Quiros-Roldan, Eugenia and Mussini, Cristina and Girardi, Enrico and Cozzi-Lepri, Alessandro and Antinori, Andrea and Puoti, Massimo and NoCo Study of the Icona cohort, NoCo Study of the Icona cohort},
  title = {Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort},
  journal = {Liver International},
  year = {2023},
  doi = {10.1111/liv.15700}
}
Kostenlos starten →